H.C. Wainwright lowered the firm’s price target on Co-Diagnostics to $1.50 from $2 and keeps a Neutral rating on the shares following the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CODX:
- Co-Diagnostics reports Q2 EPS (25c) vs. (31c) last year
- Co-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results
- Co-Diagnostics expands vector control customer base to 25 across 15 states
- Co-Diagnostics submits FDA 510(k) application for Co-Dx PCR Pro platform
- Co-Diagnostics completes first FDA 510(k) application for Co-Dx PCR Pro